(RTTNews) - New research from Novo Nordisk A/S (NVO) and Eli Lilly and Company (LLY) suggests that their GLP-1 drugs may slow down certain biological signs of aging by two to four years.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.